Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04578158

Enrollment

152

Registered

2020-10-08

Start date

2020-09-29

Completion date

2021-04-15

Last updated

2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Quercetin Phytosome, Anti-inflammatory, Immunomodulatory, Respiratory distress

Brief summary

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

Detailed description

This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30 days. It is proposed that Quercetin Phytosome will contribute to boosting the natural immunity of the subjects and will help in preventing the COVID-19 disease progression i.e preventing the need of hospitalisation.

Interventions

DRUGStandard COVID-19 care

Patients will receive standard covid-19 care as per the hospital/physician guidelines

DIETARY_SUPPLEMENTQuercetin Phytosome

Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years of either gender * Confirmed SARS-CoV-2 infection by RT-PCR * Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in self-isolation within 3 days of SARS-CoV-2 infection. * Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous cough, a loss or change to sense of smell or taste * Patients who have signed informed consent.

Exclusion criteria

* Patients with proven hypersensitivity or allergic reaction to quercetin * Manifest contrary will

Design outcomes

Primary

Measure	Time frame	Description
Percentage of subjects with COVID-19 disease progression	From day 1 to day 30	Percentage of subjects who require hospitalisation

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026